An open, randomised trial to compare desensitisation with rechallenge when restarting co-trimoxazole as prophylaxis against pneumocystis carinii pneumonia (PCP) in patients with Human Immunodeficiency Virus (HIV) infection and a history of mild to moderate cutaneous and/or febrile reactions to co-trimoxazole

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN74775699

Enrollment

388

Registered

2000-10-03

Start date

1998-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV, Acquired Immunodeficiency Syndrome (AIDS) Infections and Infestations Human immunodeficiency virus (HIV)

Interventions

Co-trimoxazole/desensitisation/direct rechallenge

Eligibility

Inclusion criteria

Inclusion criteria: 1. Past or current severe reactions to co-trimoxazole 2. Other severe skin conditions 3. Creatinine above 250 micromoles/l, Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) above five times local limit 4. Haemoglobin below 10.5 g/dl, neutrophils below 0.75, platelets below 50

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Proportion of patients still taking co-trimoxazole four and 24 weeks after trial entry	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026